The CREB-binding protein inhibitor ICG-001 suppresses pancreatic cancer growth

Molecular Cancer Therapeutics

Volumn 13, Issue 10, 2014, Pages 2303-2314

  Arensman, Michael D ^a   Telesca, Donatello ^a   Lay, Anna R ^a   Kershaw, Kathleen M ^a   Wu, Nanping ^a   Donahue, Timothy R ^a   Dawson, David W ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; GEMCITABINE; MATRILYSIN; MYC PROTEIN; N BENZYL 1,2,3,4,8,9 HEXAHYDRO 6 (4 HYDROXYBENZYL) 8 (1 NAPHTHYLMETHYL) 4,7 DIOXO 2H PYRAZINO[1,2 A]PYRIMIDINE 1(6H) CARBOXAMIDE; S PHASE KINASE ASSOCIATED PROTEIN 2; SMALL INTERFERING RNA; SURVIVIN; CREBBP PROTEIN, HUMAN; FUSED HETEROCYCLIC RINGS; PYRIMIDINONE DERIVATIVE;

ANCHORAGE INDEPENDENT GROWTH; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CANCER SURVIVAL; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DNA REPLICATION; DRUG EFFICACY; DRUG MECHANISM; DRUG PROTEIN BINDING; FEMALE; G1 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; TUMOR XENOGRAFT; WNT SIGNALING PATHWAY; ANIMAL; ANTAGONISTS AND INHIBITORS; CARCINOMA, PANCREATIC DUCTAL; DRUG EFFECTS; DRUG SCREENING; GENETICS; HUMAN; METABOLISM; NUDE MOUSE; PANCREATIC NEOPLASMS; PATHOLOGY; RANDOMIZATION; TISSUE MICROARRAY; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; BICYCLO COMPOUNDS, HETEROCYCLIC; CARCINOMA, PANCREATIC DUCTAL; CELL LINE, TUMOR; CELL PROLIFERATION; CREB-BINDING PROTEIN; FEMALE; G1 PHASE CELL CYCLE CHECKPOINTS; GENE EXPRESSION; HUMANS; MICE; MICE, NUDE; PANCREATIC NEOPLASMS; PYRIMIDINONES; RANDOM ALLOCATION; TISSUE ARRAY ANALYSIS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84921275022     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-13-1005     Document Type: Article

References (49)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10-29.
2. Vincent A, Herman J, Schulick R, Hruban RH, Goggins M. Pancreatic cancer. Lancet 2011;378:607-20.
3. Clevers H. Wnt/beta-catenin signaling in development and disease. Cell 2006;127:469-80.
4. Morris JP, Wang SC, Hebrok M. KRAS, Hedgehog, Wnt and the twisted developmental biology of pancreatic ductal adenocarcinoma. Nat Rev Cancer 2010;10:683-95.
5. White BD, Chien AJ, Dawson DW. Dysregulation of Wnt/β-catenin signaling in gastrointestinal cancers. Gastroenterology 2011;142:219-32.
6. Zhang Y, Morris JP, Yan W, Scho field HK, Gurney A, Simeone DM, et al. Canonical wnt signaling is required for pancreatic carcinogenesis. Cancer Res 2013;73:4909-22.
7. Arensman MD, Kovochich a N, Kulikauskas RM, Lay a R, Yang P-T, Li X, et al. WNT7B mediates autocrine Wnt/β-catenin signaling and anchorage-independent growth in pancreatic adenocarcinoma. Oncogene 2014;33:899-908.
8. Zeng G, Germinaro M, Micsenyi A, Monga NK, Bell A, Sood A, et al. Aberrant Wnt/beta-catenin signaling in pancreatic adenocarcinoma. Neoplasia 2006;8:279-89.
9. Pasca di Magliano M, Biankin AV, Heiser PW, Cano Da, Gutierrez PJ a, Deramaudt T, et al. Common activation of canonical Wnt signaling in pancreatic adenocarcinoma. PLoS One 2007;2:1-9.
10. Wang L, Heidt DG, Lee CJ, Yang H, Logsdon CD, Zhang L, et al. Oncogenic function of ATDC in pancreatic cancer through Wnt pathway activation and beta-catenin stabilization. Cancer Cell 2009;15:207-19.
11. Froeling FEM, Feig C, Chelala C, Dobson R, Mein CE, Tuveson D a, et al. Retinoic acid-induced pancreatic stellate cell quiescence reduces paracrine Wnt-β-catenin signaling to slow tumor progression. Gastroenterology 2011;141:1486-97.
12. Jiang X, Hao H-X, Growney JD, Woolfenden S, Bottiglio C, Ng N, et al. Inactivating mutations of RNF43 confer Wnt dependency in pancreatic ductal adenocarcinoma. Proc Natl Acad Sci U S A 2013;110:12649-54.
13. Gurney A, Axelrod F, Bond CJ, Cain J, Chartier C, Donigan L, et al. Wnt pathway inhibition via the targeting of Frizzled receptors results in decreased growth and tumorigenicity of human tumors. Proc Natl Acad Sci U S A 2012;109:11717-22.
14. Voronkov A, Krauss S. Wnt/beta-catenin signaling and small molecule inhibitors. Curr Pharm Des 2013;19:634-64.
15. Anastas JN, Moon RT. WNTsignalling pathways as therapeutic targets in cancer. Nat Rev Cancer 2013;13:11-26.
16. Emami KH, Nguyen C, Ma H, Kim DH, Jeong KW, Eguchi M, et al. A small molecule inhibitor of beta-catenin/CREB-binding protein transcription [corrected]. Proc Natl Acad Sci U S A 2004;101:12682-7.
17. Lazarova DL, Chiaro C, Wong T, Drago E, Rainey A, O'Malley S, et al. CBP activity mediates effects of the histone deacetylase inhibitor butyrate on WNT activity and apoptosis in colon cancer cells. J Cancer 2013;4:481-90.
18. Lazarova DL, Wong T, Chiaro C, Drago E, Bordonaro M. p300 influences butyrate-mediated WNT hyperactivation in colorectal cancer cells. J Cancer 2013;4:491-501.
19. Ma H, Nguyen C, Lee K-S, Kahn M. Differential roles for the coactivators CBP and p300 on TCF/beta-catenin-mediated survivin gene expression. Oncogene 2005;24:3619-31.
20. Henderson WR, Chi EY, Ye X, Nguyen C, Tien Y, Zhou B, et al. Inhibition of Wnt/beta-catenin/CREB binding protein (CBP) signaling reverses pulmonary fibrosis. Proc Natl Acad Sci U S A 2010;107:14309-14.
21. Hao S, He W, Li Y, Ding H, Hou Y, Nie J, et al. Targeted inhibition of β-catenin/CBP signaling ameliorates renal interstitial fibrosis. J Am Soc Nephrol 2011;22:1642-53.
22. Gang EJ, Hsieh Y-T, Pham J, Zhao Y, Nguyen C, Huantes S, et al. Small-molecule inhibition of CBP/catenin interactions eliminates drug-resistant clones in acute lymphoblastic leukemia. Oncogene 2014;33:2169-78.
23. Sasaki T, Hwang H, Nguyen C, Kloner RA, Kahn M. The small molecule Wnt signaling modulator ICG-001 improves contractile function in chronically infarcted rat myocardium. PLoS One 2013;8:e75010.
24. Beyer C, Reichert H, Akan H, Mallano T, Schramm A, Dees C, et al. Blockade of canonical Wnt signalling ameliorates experimental dermal fibrosis. Ann Rheum Dis 2013;72:1255-8.
25. Wend P, Fang L, Zhu Q, Schipper JH, Loddenkemper C, Kosel F, et al. Wnt/β-catenin signalling induces MLL to create epigenetic changes in salivary gland tumours. EMBO J 2013;32:1977-89.
26. Takahashi-Yanaga F, Kahn M. Targeting Wnt signaling: can we safely eradicate cancer stem cells? Clin Cancer Res 2010;16:3153-62.
27. Kim MP, Evans DB, Wang H, Abbruzzese JL, Fleming JB, Gallick GE. Generation of orthotopic and heterotopic human pancreatic cancer xenografts in immunodeficient mice. Nat Protoc 2009;4:1670-80.
28. Foltz C, Ullman-Cullere M. Guidelines for assessing the health and condition of mice. Lab Anim (NY) 1999;28:28-32.
29. Hotz HG, Reber HA, Hotz B, Yu T, Foitzik T, Buhr HJ, et al. An orthotopic nude mouse model for evaluating pathophysiology and therapy of pancreatic cancer. Pancreas 2003;26.
30. Guo R, Xu D, Wang W. Identi fication and analysis of new proteins involved in the DNA damage response network of Fanconi anemia and Bloom syndrome. Methods 2009;48:72-9.
31. Li C, Wong WH. Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection. Proc Natl Acad Sci U S A 2001;98:31-6.
32. Huang DW, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2009;4:44-57.
33. Biechele TL, Moon RT. Assaying beta-catenin/TCF transcription with beta-catenin/TCF transcription-based reporter constructs. Methods Mol Biol 2008;468:99-110.
34. Yu M, Ting DT, Stott SL, Wittner BS, Ozsolak F, Paul S, et al. RNA sequencing of pancreatic circulating tumour cells implicates WNT signalling in metastasis. Nature 2012;487:510-3.
35. Dickson MA. Molecular pathways: CDK4 inhibitors for cancer therapy. Clin Cancer Res 2014;20:3379-83.
36. Mini E, Nobili S, Caciagli B, Landini I, Mazzei T. Cellular pharmacology of gemcitabine. Ann Oncol 2006;17:v7-12.
37. Xie H, Jiang W, Jiang J, Wang Y, Kim R, Liu X, et al. Predictive and prognostic roles of ribonucleotide reductase M1 in resectable pancreatic adenocarcinoma. Cancer 2013;119:173-81.
38. Wei CH, Gorgan TR, Elashoff DA, Hines OJ, Farrell JJ, Donahue TR. A meta-analysis of gemcitabine biomarkers in patients with pancreaticobiliary cancers. Pancreas 2013;42:1303-10.
39. McMillan M, Kahn M. Investigating Wnt signaling: a chemogenomic safari. Drug Discov Today 2005;10:1467-74.
40. Kahn M. Symmetric division versus asymmetric division: a tale of two coactivators. Future Med Chem 2011;3:1745-63.
41. Miyabayashi T, Teo J, Yamamoto M, Mcmillan M, Nguyen C, Kahn M. Wnt/-catenin/CBP signaling maintains long-term murine embryonic stem cell pluripotency. Proc Natl Acad Sci 2007;104:5668-73.
42. Bailey JM, Alsina J, Rasheed Z a, McAllister FM, Fu Y-Y, Plentz R, et al. DCLK1 marks a morphologically distinct subpopulation of cells with stem cell properties in pre-invasive pancreatic cancer. Gastroenterology 2014;146:245-56.
43. Goodman RH, Smolik S. CBP/p300 in cell growth, transformation, and development. Genes Dev 2000;14:1553-77.
44. Kim Y-M, Ma H, Oehler VG, Gang EJ, Nguyen C, Masiello D, et al. The gamma catenin/CBP complex maintains survivin transcription in β-catenin deficient/depleted cancer cells. Curr Cancer Drug Targets 2011;11:213-25.
45. Ait-Si-Ali S, Polesskaya a, Filleur S, Ferreira R, Duquet a, Robin P, et al. CBP/p300 histone acetyl-transferase activity is important for the G1/S transition. Oncogene 2000;19:2430-7.
46. Chan C-H, Lee S-W, Wang J, Lin H-K. Regulation of Skp2 expression and activity and its role in cancer progression. Sci World J 2010;10:1001-15.
47. Hurlin PJ, Huang J. The MAX-interacting transcription factor network. Semin Cancer Biol 2006;16:265-74.
48. Faiola F, Liu X, Lo S, Pan S, Zhang K, Lymar E, et al. Dual regulation of MYC by p300 via acetylation-dependent control of myc protein turnover and coactivation of myc-induced transcription. Mol Cell Biol 2005;25:10220-34.
49. Jin J, Harper JW. A license to kill: transcriptional activation and enhanced turnover of Myc by the SCF(kp2) ubiquitin ligase. Cancer Cell 2003;3:517-8.